Gastric Cancer Clinical Trials in Orange, California

7 studies are recruiting for gastric cancer in Orange, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

   The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Orange, California

   Locations

   311 in total

   Run by

   AstraZeneca

   See if you can join NCT07431281 on ClinicalTrials.gov

2. AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

   The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Research Site, Orange, California

   Locations

   52 in total

   Run by

   AstraZeneca

   See if you can join NCT06219941 on ClinicalTrials.gov

3. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

   This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California

   Locations

   62 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT05208762 on ClinicalTrials.gov

4. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

   This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole bra…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT06580002 on ClinicalTrials.gov

5. Combination of TATE and PD-1 Inhibitor in Liver Cancer

   This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellula…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   University of California, Irvine, Orange, California

   Locations

   3 in total

   Run by

   Teclison Ltd.

   See if you can join NCT03259867 on ClinicalTrials.gov

6. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

   This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stern Center for Cancer Clinical Trials and Research, Orange, California

   Locations

   21 in total

   Run by

   I-Mab Biopharma US Limited

   See if you can join NCT04900818 on ClinicalTrials.gov

7. 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

   This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patient…

   Stage

   Phase 1

   Ages

   15 and older

   Site

   UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California

   Locations

   5 in total

   Run by

   Lantheus Medical Imaging

   See if you can join NCT06298916 on ClinicalTrials.gov